Novartis (NVS) Competitors

Novartis has a net margin of 23.29% compared to Johnson & Johnson's net margin of 21.48%. Novartis' return on equity of 38.56% beat Johnson & Johnson's return on equity.

Novartis has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

13.1% of Novartis shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.2%. Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.1%. Novartis pays out 46.5% of its earnings in the form of a dividend. Johnson & Johnson pays out 62.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 64 consecutive years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Johnson & Johnson has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

In the previous week, Johnson & Johnson had 35 more articles in the media than Novartis. MarketBeat recorded 56 mentions for Johnson & Johnson and 21 mentions for Novartis. Johnson & Johnson's average media sentiment score of 0.63 beat Novartis' score of 0.60 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Novartis currently has a consensus target price of $148.40, indicating a potential upside of 5.72%. Johnson & Johnson has a consensus target price of $275.87, indicating a potential upside of 7.39%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than Novartis.

Merck & Co., Inc. has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Novartis currently has a consensus price target of $148.40, suggesting a potential upside of 5.72%. Merck & Co., Inc. has a consensus price target of $145.76, suggesting a potential upside of 1.38%. Given Novartis' higher possible upside, equities research analysts plainly believe Novartis is more favorable than Merck & Co., Inc..

Novartis has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

13.1% of Novartis shares are owned by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Novartis has a net margin of 23.29% compared to Merck & Co., Inc.'s net margin of 4.77%. Novartis' return on equity of 38.56% beat Merck & Co., Inc.'s return on equity.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.2%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.4%. Novartis pays out 46.5% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 272.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has increased its dividend for 14 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Merck & Co., Inc. had 13 more articles in the media than Novartis. MarketBeat recorded 34 mentions for Merck & Co., Inc. and 21 mentions for Novartis. Novartis' average media sentiment score of 0.60 beat Merck & Co., Inc.'s score of 0.43 indicating that Novartis is being referred to more favorably in the media.

Novartis has lower revenue, but higher earnings than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Astrazeneca currently has a consensus price target of $206.67, suggesting a potential upside of 31.58%. Novartis has a consensus price target of $148.40, suggesting a potential upside of 5.72%. Given Astrazeneca's stronger consensus rating and higher probable upside, research analysts clearly believe Astrazeneca is more favorable than Novartis.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.8%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.2%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Novartis pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Astrazeneca has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Novartis has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Astrazeneca had 7 more articles in the media than Novartis. MarketBeat recorded 28 mentions for Astrazeneca and 21 mentions for Novartis. Novartis' average media sentiment score of 0.60 beat Astrazeneca's score of 0.35 indicating that Novartis is being referred to more favorably in the news media.

Novartis has a net margin of 23.29% compared to Astrazeneca's net margin of 17.02%. Novartis' return on equity of 38.56% beat Astrazeneca's return on equity.

Novo Nordisk A/S has a net margin of 35.36% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 58.61% beat Novartis' return on equity.

Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Novartis presently has a consensus price target of $148.40, suggesting a potential upside of 5.72%. Novo Nordisk A/S has a consensus price target of $102.85, suggesting a potential upside of 175.42%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

13.1% of Novartis shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.2%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.2%. Novartis pays out 46.5% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Novo Nordisk A/S had 29 more articles in the media than Novartis. MarketBeat recorded 50 mentions for Novo Nordisk A/S and 21 mentions for Novartis. Novartis' average media sentiment score of 0.60 beat Novo Nordisk A/S's score of 0.46 indicating that Novartis is being referred to more favorably in the media.

Novartis has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.